Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non‐small<scp>‐</scp>cell lung cancer in KEYNOTE‐407
Shunichi Sugawara(Sendai Kousei Hospital), Terufumi Kato(Taipei Veterans General Hospital), Kadoaki Ohashi(Okayama University Hospital), Morihito Okada(Hiroshima University), Hibiki Udagawa(National Cancer Center Hospital East), Kazuo Kasahara(Nippon Medical School), Kazuma Kishi(Toho University), Nobuyuki Yamamoto(Wakayama Medical University), Miyako Satouchi(Memorial Sloan Kettering Cancer Center), Fumio Imamura(Osaka International Cancer Institute), Paul Schwarzenberger(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yukio Hosomi(Tokyo Metropolitan Komagome Hospital), Takuma Yokoyama(Kyorin University Hospital), Takayasu Kurata(Kansai Medical University), Kazuo Noguchi(MSD K.K. (Japan)), Hidehito Horinouchi(Tokyo National Hospital), Tatsuro Fukuhara(Miyagi Prefectural Hospital Organization), Makoto Nishio(Japanese Foundation For Cancer Research), Takaaki Tokito(Kurume University), Yasuharu Nakahara(Himeji Medical Center), Kentaro Tanaka(Institute for the Future), Hiroshi Tanaka(Tokyo Medical and Dental University), Hideo Saka(Nagoya Medical Center), Nobuyuki Katakami(Takarazuka City Hospital), Tomonori Hirashima(Osaka Prefectural Medical Center), Noriaki Adachi(MSD K.K. (Japan)), Keisuke Aoe(National Sanyo Hospital), Kyoichi Okishio(NHO Kinki Chuo Chest Medical Center)
Cited by 16
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k